MX2024007301A - Peptidos y metodos para usar en el tratamiento del dolor. - Google Patents
Peptidos y metodos para usar en el tratamiento del dolor.Info
- Publication number
- MX2024007301A MX2024007301A MX2024007301A MX2024007301A MX2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- methods
- pain treatment
- kits
- modulating
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306835 | 2021-12-17 | ||
| PCT/EP2022/086559 WO2023111348A1 (en) | 2021-12-17 | 2022-12-19 | Peptides and methods for use in treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007301A true MX2024007301A (es) | 2024-06-26 |
Family
ID=79317102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007301A MX2024007301A (es) | 2021-12-17 | 2022-12-19 | Peptidos y metodos para usar en el tratamiento del dolor. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250051395A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4447991A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024547029A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240126864A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118401249A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129864A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022413983A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3239578A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313183A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007301A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202344689A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023111348A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026119985A1 (en) * | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating wounds and inflammatory diseases |
| WO2026119983A1 (en) * | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating pain, wounds and inflammatory diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| WO2006013462A2 (en) * | 2004-07-30 | 2006-02-09 | Nsgene A/S | Growth factors nsg28, nsg30, and nsg32 |
| EP2801369A1 (en) | 2013-05-06 | 2014-11-12 | Centre National De La Recherche Scientifique | TAFA4 compounds and uses thereof for treating pain |
| CN108699604A (zh) | 2016-03-08 | 2018-10-23 | 艾克斯-马赛大学 | 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途 |
-
2022
- 2022-12-19 CA CA3239578A patent/CA3239578A1/en active Pending
- 2022-12-19 MX MX2024007301A patent/MX2024007301A/es unknown
- 2022-12-19 US US18/719,934 patent/US20250051395A1/en active Pending
- 2022-12-19 AR ARP220103509A patent/AR129864A1/es unknown
- 2022-12-19 IL IL313183A patent/IL313183A/en unknown
- 2022-12-19 WO PCT/EP2022/086559 patent/WO2023111348A1/en not_active Ceased
- 2022-12-19 JP JP2024536410A patent/JP2024547029A/ja active Pending
- 2022-12-19 AU AU2022413983A patent/AU2022413983A1/en active Pending
- 2022-12-19 CN CN202280083300.3A patent/CN118401249A/zh active Pending
- 2022-12-19 KR KR1020247023481A patent/KR20240126864A/ko active Pending
- 2022-12-19 TW TW111148815A patent/TW202344689A/zh unknown
- 2022-12-19 EP EP22840601.3A patent/EP4447991A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202344689A (zh) | 2023-11-16 |
| JP2024547029A (ja) | 2024-12-26 |
| AU2022413983A1 (en) | 2024-06-13 |
| KR20240126864A (ko) | 2024-08-21 |
| CA3239578A1 (en) | 2023-06-22 |
| CN118401249A (zh) | 2024-07-26 |
| AR129864A1 (es) | 2024-10-09 |
| US20250051395A1 (en) | 2025-02-13 |
| EP4447991A1 (en) | 2024-10-23 |
| WO2023111348A1 (en) | 2023-06-22 |
| IL313183A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| MX2023009521A (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d. | |
| CL2019002220A1 (es) | Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos. | |
| MX2021007948A (es) | Inhibidores de proteina de activacion de fibroblastos. | |
| MX2022001933A (es) | Inhibidores de enzimas. | |
| MX2022009435A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares. | |
| MX2024002989A (es) | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il )-benzonitrilo. | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| CL2023003259A1 (es) | Composiciones y métodos para el tratamiento de la depresión. | |
| BR112022015768A2 (pt) | Métodos de tratamento e prevenção de arritmias de enxerto | |
| EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
| MX2024014419A (es) | Peptidos y metodos para usar en el tratamiento del dolor | |
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| AR128163A1 (es) | Ácido láctico y análogos del mismo para uso en regular y/o promover el aumento de tejidos | |
| MX2025001990A (es) | Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico | |
| CL2025000127A1 (es) | Uso de aficamten para tratar la miocardiopatía hipertrófica no obstructiva. | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| CO2022014199A2 (es) | Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19 | |
| AR129864A1 (es) | Péptidos y métodos para uso en tratar el dolor | |
| MX2025014063A (es) | Inhibidores de expresion y/o funcion | |
| MX2024004416A (es) | Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. | |
| MX2025006287A (es) | Trehalosa para el tratamiento de la enfermedad de huntington | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. |